Healthcare Industry News: SUTENT
News Release - October 27, 2006
S*BIO Appoints Joy Zhu Senior Vice President of Global Clinical Development
SINGAPORE, Oct. 27 (HSMN NewsFeed) -- S*BIO Pte Ltd, a privately held biotech company focused on the research and clinical development of novel targeted small molecule drugs for the treatment of cancer, today announced the appointment of Joy Zhu, MD to the role of Senior Vice President of Global Clinical Development. As a member of S*BIO's management team, Dr. Zhu will be responsible for leading all clinical development strategies and activities for compounds from Phase 1 to Phase 4.As head of the oncology clinical research group, Dr. Zhu brings extensive experience in all aspects of drug development including planning and conducting all phases of pharmaceutical clinical studies in the US and around the world. Prior to joining S*BIO, Dr. Zhu was Senior Medical Director at Scios (J & J), and responsible for clinical development strategies for their oncology clinical program, pre-IND planning, and the oversight of all clinical data. In her previous leadership role at Sugen (Pfizer), she made significant contributions to the approval of SUTENT® indicated for renal cell carcinoma. At Amgen, Dr. Zhu was Global Development Leader for the AMG 162 (a fully human antibody) oncology clinical program, demonstrating great success in leading global studies from Phase 1 to Phase 3. At Novartis, Dr. Zhu was responsible for two successful NDA submissions for ophthalmic drugs (Zaditor® and Rescula®), both approved by FDA within six months.
Dr. Zhu received her M.D. from Beijing Medical University and her Ph.D. in Biochemistry from Georgia Institute of Technology.
About S*BIO Pte Ltd
S*BIO is a privately held biotech company focused on the research and clinical development of novel targeted small molecule drugs for the treatment of cancer with leading programs around histone deacetylases (HDAC) and kinases. S*BIO intends to become a leading fully integrated oncology-focused biotech company in Asia Pacific.
S*BIO has developed a fully integrated state-of-the-art R&D infrastructure and expertise to support its efforts in oncology. In anticipation of delivering its first IND in 2006, S*BIO is building a strong clinical development team and is actively fostering close ties with medical oncology networks in Asia Pacific. The Company is aggressively building a pipeline of internal and in-licensed compounds.
More information about S*BIO can be found at http://www.sbio.com
Source: S*BIO
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
